{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T08:44:10Z","timestamp":1782722650216,"version":"3.54.5"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100007303","name":"University of Balamand","doi-asserted-by":"publisher","award":["RGA\/FHS\/21-22\/008"],"award-info":[{"award-number":["RGA\/FHS\/21-22\/008"]}],"id":[{"id":"10.13039\/501100007303","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Syst Rev"],"DOI":"10.1186\/s13643-026-03190-1","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T01:07:12Z","timestamp":1778029632000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Macrolides usage as anti-inflammatory agents in the treatment of community-acquired pneumonia and ventilator-associated pneumonia: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"15","author":[{"given":"Ramona","family":"Nasr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abir Abdel","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisrine","family":"ElHadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Salameh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanine","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"issue":"6","key":"3190_CR1","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S2213-2600(20)30080-1","volume":"8","author":"TDY Reijnders","year":"2020","unstructured":"Reijnders TDY, Saris A, Schultz MJ, van der Poll T. Immunomodulation by macrolides: therapeutic potential for critical care. Lancet Respir Med. 2020Jun 1;8(6):619\u201330.","journal-title":"Lancet Respir Med"},{"issue":"1","key":"3190_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s11908-007-0016-1","volume":"9","author":"DP Healy","year":"2007","unstructured":"Healy DP. Macrolide immunomodulation of chronic respiratory diseases. Curr Infect Dis Rep. 2007Jan 1;9(1):7\u201313.","journal-title":"Curr Infect Dis Rep"},{"issue":"17","key":"3190_CR3","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1056\/NEJMra1312885","volume":"371","author":"DM Musher","year":"2014","unstructured":"Musher DM, Thorner AR. Community-Acquired Pneumonia. N Engl J Med. 2014Oct 23;371(17):1619\u201328.","journal-title":"N Engl J Med"},{"issue":"9998","key":"3190_CR4","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/S0140-6736(15)60733-4","volume":"386","author":"E Prina","year":"2015","unstructured":"Prina E, Ranzani OT, Torres A. Community-acquired pneumonia. The Lancet. 2015Sep 12;386(9998):1097\u2013108.","journal-title":"The Lancet"},{"issue":"11","key":"3190_CR5","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1093\/cid\/cix647","volume":"65","author":"JA Ramirez","year":"2017","unstructured":"Ramirez JA, Wiemken TL, Peyrani P, Arnold FW, Kelley R, Mattingly WA, et al. Adults Hospitalized With Pneumonia in the United States: Incidence, Epidemiology, and Mortality. Clin Infect Dis. 2017Nov 13;65(11):1806\u201312.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"3190_CR6","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1093\/cid\/ciw353","volume":"63","author":"AC Kalil","year":"2016","unstructured":"Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016Sep 1;63(5):e61-111.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"3190_CR7","doi-asserted-by":"publisher","first-page":"633","DOI":"10.3949\/ccjm.87a.19117","volume":"87","author":"AR Modi","year":"2020","unstructured":"Modi AR, Kovacs CS. Hospital-acquired and ventilator-associated pneumonia: Diagnosis, management, and prevention. Cleve Clin J Med. 2020Oct 1;87(10):633\u20139.","journal-title":"Cleve Clin J Med"},{"key":"3190_CR8","doi-asserted-by":"crossref","unstructured":"Torres A, Niederman MS, Chastre J, Ewig S, Fernandez-Vandellos P, Hanberger H, et al. International ERS\/ESICM\/ESCMID\/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)\/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociaci\u00f3n Latinoamericana del T\u00f3rax (ALAT). Eur Respir J. 2017 Sep 1 Cited 2024 Jun 27;50(3). Available from: https:\/\/erj.ersjournals.com\/content\/50\/3\/1700582","DOI":"10.1183\/13993003.00582-2017"},{"issue":"13","key":"3190_CR9","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1056\/NEJMoa1306801","volume":"370","author":"SS Magill","year":"2014","unstructured":"Magill SS, Edwards JR, Bamberg W, Beldavs ZG, Dumyati G, Kainer MA, et al. Multistate point-prevalence survey of health care\u2013associated infections. N Engl J Med. 2014;370(13):1198\u2013208.","journal-title":"N Engl J Med"},{"key":"3190_CR10","unstructured":"Infections Disease Society of America (IDSA). Community-Acquired Pneumonia (CAP) Clinical Pathway Overview Presentation. 2023 Oct 31 Cited 2024 Jul 12. Available from: https:\/\/www.idsociety.org\/multimedia\/all-videos\/community-acquired-pneumonia-cap-clinical-pathway-overview-presentation\/"},{"issue":"4","key":"3190_CR11","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1007\/s00134-009-1730-y","volume":"36","author":"I Martin-Loeches","year":"2010","unstructured":"Martin-Loeches I, Lisboa T, Rodriguez A, Putensen C, Annane D, Garnacho-Montero J, et al. Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med. 2010;36(4):612\u201320.","journal-title":"Intensive Care Med"},{"issue":"2","key":"3190_CR12","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1093\/cid\/cir274","volume":"53","author":"JD Chalmers","year":"2011","unstructured":"Chalmers JD, Taylor JK, Singanayagam A, Fleming GB, Akram AR, Mandal P, et al. Epidemiology, Antibiotic Therapy, and Clinical Outcomes in Health Care-Associated Pneumonia: A UK Cohort Study. Clin Infect Dis. 2011Jul 15;53(2):107\u201313.","journal-title":"Clin Infect Dis"},{"key":"3190_CR13","doi-asserted-by":"crossref","unstructured":"Brito V, Niederman MS. How Does One Diagnose and Manage Severe Community-Acquired Pneumonia? Evid-Based Pract Crit Care. 2011;253\u201362.","DOI":"10.1016\/B978-1-4160-5476-4.00038-9"},{"issue":"1","key":"3190_CR14","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1183\/09031936.00054108","volume":"33","author":"MI Restrepo","year":"2009","unstructured":"Restrepo MI, Mortensen EM, Waterer GW, Wunderink RG, Coalson JJ, Anzueto A. Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur Respir J. 2009Jan 1;33(1):153\u20139.","journal-title":"Eur Respir J"},{"issue":"4","key":"3190_CR15","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.chest.2018.11.006","volume":"155","author":"A Ceccato","year":"2019","unstructured":"Ceccato A, Cilloniz C, Martin-Loeches I, Ranzani OT, Gabarrus A, Bueno L, et al. Effect of combined \u03b2-Lactam\/macrolide therapy on mortality according to the microbial etiology and inflammatory status of patients with community-acquired pneumonia. Chest. 2019;155(4):795\u2013804.","journal-title":"Chest"},{"issue":"2","key":"3190_CR16","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1097\/CCM.0b013e3182a66b9b","volume":"42","author":"WI Sligl","year":"2014","unstructured":"Sligl WI, Asadi L, Eurich DT, Tjosvold L, Marrie TJ, Majumdar SR. Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and meta-analysis. Crit Care Med. 2014;42(2):420.","journal-title":"Crit Care Med"},{"issue":"1","key":"3190_CR17","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s00408-015-9822-7","volume":"194","author":"FW Arnold","year":"2016","unstructured":"Arnold FW, Bordon J, Fernandez-Botran R, Rane MJ, Uriarte SM, Kelley R, et al. Macrolide use and neutrophil function\/cytokine levels in hospitalized patients with community-acquired pneumonia: a pilot study. Lung. 2016;194(1):155\u201362.","journal-title":"Lung"},{"issue":"2","key":"3190_CR18","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0000000000000788","volume":"27","author":"TT Gilbert","year":"2020","unstructured":"Gilbert TT, Arfstrom RJ, Mihalovic SW, Dababneh AS, Varatharaj Palraj BR, Dierkhising RA, et al. Effect of \u03b2-Lactam plus macrolide versus fluoroquinolone on 30-day readmissions for community-acquired pneumonia. Am J Ther. 2020;27(2):e177.","journal-title":"Am J Ther"},{"issue":"372","key":"3190_CR19","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/bmj.n71","volume":"29","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021Mar;29(372):71.","journal-title":"BMJ"},{"key":"3190_CR20","doi-asserted-by":"crossref","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JPA, et al. The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration. Ann Intern Med. 2009;151(4):W-65.","DOI":"10.7326\/0003-4819-151-4-200908180-00136"},{"key":"3190_CR21","unstructured":"Mansour H, Abdel Rahman A, Al-Shaer M, Chaar M, Kahale L, El-Hadi N. Macrolides usage as anti-inflammatory agents in the treatment of community acquired pneumonia and ventilator associated pneumonia: a systematic review. PROSPERO 2018 CRD42018088203. 2018 Cited 2024 Jun 27; Available from: https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42018088203"},{"issue":"1","key":"3190_CR22","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2307\/2529310","volume":"33","author":"JR Landis","year":"1977","unstructured":"Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159\u201374.","journal-title":"Biometrics"},{"issue":"9","key":"3190_CR23","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","volume":"73","author":"K Slim","year":"2003","unstructured":"Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (MINORS): development and validation of a new instrument. ANZ J Surg. 2003;73(9):712\u20136.","journal-title":"ANZ J Surg"},{"issue":"1","key":"3190_CR24","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/jebm.12141","volume":"8","author":"X Zeng","year":"2015","unstructured":"Zeng X, Zhang Y, Kwong JSW, Zhang C, Li S, Sun F, et al. The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. J Evid Based Med. 2015;8(1):2\u201310.","journal-title":"J Evid Based Med"},{"issue":"7","key":"3190_CR25","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.jclinepi.2013.02.003","volume":"66","author":"JC Andrews","year":"2013","unstructured":"Andrews JC, Sch\u00fcnemann HJ, Oxman AD, Pottie K, Meerpohl JJ, Coello PA, et al. GRADE guidelines: 15. Going from evidence to recommendation\u2014determinants of a recommendation\u2019s direction and strength. J Clin Epidemiol. 2013;66(7):726\u201335.","journal-title":"J Clin Epidemiol"},{"key":"3190_CR26","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.jcrc.2017.08.048","volume":"43","author":"JM Pereira","year":"2018","unstructured":"Pereira JM, Gon\u00e7alves-Pereira J, Ribeiro O, Baptista JP, Froes F, Paiva JA. Impact of antibiotic therapy in severe community-acquired pneumonia: data from the Infauci study. J Crit Care. 2018;43:183\u20139.","journal-title":"J Crit Care"},{"issue":"5","key":"3190_CR27","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1183\/09031936.06.00126004","volume":"27","author":"J Aspa","year":"2006","unstructured":"Aspa J, Rajas O, Rodriguez De Castro F, Huertas MC, Border\u00edas L, Cabello FJ, et al. Impact of initial antibiotic choice on mortality from pneumococcal pneumonia. Eur Respir J. 2006;27(5):1010\u20139.","journal-title":"Eur Respir J"},{"issue":"8","key":"3190_CR28","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1086\/529439","volume":"46","author":"EJ Giamarellos-Bourboulis","year":"2008","unstructured":"Giamarellos-Bourboulis EJ, Pech\u00e8re J, Routsi C, Plachouras D, Kollias S, Raftogiannis M, et al. Effect of Clarithromycin in Patients with Sepsis and Ventilator-Associated Pneumonia. Clin Infect Dis. 2008Apr 15;46(8):1157\u201364.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"3190_CR29","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12931-015-0165-y","volume":"16","author":"MJ Lorenzo","year":"2015","unstructured":"Lorenzo MJ, Moret I, Sarria B, Cases E, Cortijo J, M\u00e9ndez R, et al. Lung inflammatory pattern and antibiotic treatment in pneumonia. Respir Res. 2015;16(1):15.","journal-title":"Respir Res"},{"issue":"5","key":"3190_CR30","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1093\/jac\/dkp088","volume":"63","author":"A Tessmer","year":"2009","unstructured":"Tessmer A, Welte T, Martus P, Schnoor M, Marre R, Suttorp N. Impact of intravenous \u03b2-lactam\/macrolide versus \u03b2-lactam monotherapy on mortality in hospitalized patients with community-acquired pneumonia. J Antimicrob Chemother. 2009Mar 5;63(5):1025\u201333.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"3190_CR31","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/j.1440-1843.2005.00704.x","volume":"10","author":"L Loh","year":"2005","unstructured":"Loh L, Quah S, Khoo S, Vijayasingham P, Thayaparan T. Addition of macrolide in treating adult hospitalized community\u2010acquired pneumonia. Respirology. 2005;10(3):371\u20137.","journal-title":"Respirology"},{"issue":"21","key":"3190_CR32","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1001\/archinte.159.21.2576","volume":"159","author":"JE Stahl","year":"1999","unstructured":"Stahl JE, Barza M, DesJardin J, Martin R, Eckman MH. Effect of Macrolides as Part of Initial Empiric Therapy on Length of Stay in Patients Hospitalized With Community-Acquired Pneumonia. Arch Intern Med. 1999Nov 22;159(21):2576.","journal-title":"Arch Intern Med"},{"issue":"4","key":"3190_CR33","first-page":"458","volume":"14","author":"D Yadegarynia","year":"2022","unstructured":"Yadegarynia D, Tehrani S, Maghsoudi Nejad F, Shojaeian F, Keyvanfar A. Levofloxacin versus ceftriaxone and azithromycin for treating community-acquired pneumonia: a randomized clinical trial study. Iran J Microbiol. 2022Aug 14;14(4):458\u201365.","journal-title":"Iran J Microbiol"},{"issue":"3","key":"3190_CR34","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1183\/09031936.00031007","volume":"30","author":"M Paul","year":"2007","unstructured":"Paul M, Nielsen AD, Gafter-Gvili A, Tacconelli E, Andreassen S, Almanasreh N, et al. The need for macrolides in hospitalised community-acquired pneumonia: propensity analysis. Eur Respir J. 2007Sep 1;30(3):525\u201331.","journal-title":"Eur Respir J"},{"issue":"12","key":"3190_CR35","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1093\/jac\/dkad301","volume":"78","author":"AG Kinney","year":"2023","unstructured":"Kinney AG, Scherrer NK, Sarkar S, Jain P, Wen S, Hadique S. \u03b2-Lactams plus doxycycline versus azithromycin for treatment of severe community-acquired pneumonia in critically ill patients. J Antimicrob Chemother. 2023Dec 1;78(12):2816\u201323.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"3190_CR36","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1093\/cid\/cis414","volume":"55","author":"L Asadi","year":"2012","unstructured":"Asadi L, Sligl WI, Eurich DT, Colmers IN, Tjosvold L, Marrie TJ, et al. Macrolide-Based Regimens and Mortality in Hospitalized Patients With Community-Acquired Pneumonia: A Systematic Review and Meta-analysis. Clin Infect Dis. 2012Aug 1;55(3):371\u201380.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"3190_CR37","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1164\/rccm.200311-1578OC","volume":"170","author":"LM Baddour","year":"2004","unstructured":"Baddour LM, Yu VL, Klugman KP, Feldman C, Ortqvist A, Rello J, et al. Combination Antibiotic Therapy Lowers Mortality among Severely Ill Patients with Pneumococcal Bacteremia. Am J Respir Crit Care Med. 2004Aug 15;170(4):440\u20134.","journal-title":"Am J Respir Crit Care Med"},{"key":"3190_CR38","doi-asserted-by":"publisher","unstructured":"Rubin BK, Shinkai M, editors. Macrolides as Immunomodulatory Agents. Cham: Springer International Publishing; 2024 Cited 2024 Jun 27. (Progress in Inflammation Research; vol. 92). Available from: https:\/\/link.springer.com\/https:\/\/doi.org\/10.1007\/978-3-031-42859-3","DOI":"10.1007\/978-3-031-42859-3"},{"issue":"7","key":"3190_CR39","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1021\/acs.accounts.1c00020","volume":"54","author":"AG Myers","year":"2021","unstructured":"Myers AG, Clark RB. Discovery of Macrolide Antibiotics Effective against Multi-Drug Resistant Gram-Negative Pathogens. Acc Chem Res. 2021Apr 6;54(7):1635\u201345.","journal-title":"Acc Chem Res"},{"issue":"1","key":"3190_CR40","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s13054-016-1414-2","volume":"20","author":"J Phua","year":"2016","unstructured":"Phua J, Dean NC, Guo Q, Kuan WS, Lim HF, Lim TK. Severe community-acquired pneumonia: timely management measures in the first 24 hours. Crit Care. 2016Aug 28;20(1):237.","journal-title":"Crit Care"},{"issue":"5","key":"3190_CR41","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00228-011-1161-x","volume":"68","author":"P Zarogoulidis","year":"2012","unstructured":"Zarogoulidis P, Papanas N, Kioumis I, Chatzaki E, Maltezos E, Zarogoulidis K. Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases. Eur J Clin Pharmacol. 2012May 1;68(5):479\u2013503.","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13643-026-03190-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-026-03190-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-026-03190-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T07:46:16Z","timestamp":1782719176000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13643-026-03190-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3190"],"URL":"https:\/\/doi.org\/10.1186\/s13643-026-03190-1","relation":{},"ISSN":["2046-4053"],"issn-type":[{"value":"2046-4053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]},"assertion":[{"value":"12 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"193"}}